The RIDD trial aims to test whether the progression of Dupuytren’s disease can be halted or slowed by treatment with anti-TNF injection. Currently, Dupuytren’s disease is left to progress until the finger deformity is severe enough to warrant a surgical procedure in hospital. If successful, anti-TNF treatment would prevent loss of hand function and the need for surgery, and would allow patients to be treated conveniently and quickly.
Apologies to all those who have been waiting to find out the results of the RIDD trial.
Please click on this link to see a video of Professor Jagdeep Nanchahal presenting at the International Dupuytren Symposium 2021 (Session 6) 1st December 2021.
The message of this presentation is that the RIDD phase 2b clinical trial met the primary endpoint of nodule hardness and the secondary endpoint of nodule size using ultrasound scan, with statistically significant differences between the adalimumab and placebo groups.
The full results have been submitted for publication in a peer reviewed journal and will be shared once this has been accepted and published.
There is also a discussion video which has some interesting questions from the panel and is worth a watch.
Thank you once again to all of those that have been invovled with the RIDD trial.